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Paracoccidioidomycosis (PCM) is the most prevalent systemic mycosis in Latin America. Patients with PCM
show a wide spectrum of clinical and pathological manifestations depending on both host and pathogen factors.
Two clinical forms of the disease are recognized: the acute or juvenile form and the chronic or adult form. The
major antigenic component of the parasite is a glycoprotein of 43 kDa (gp43). All patient sera present
antibodies against gp43 (anti-gp43) and, as demonstrated before by our group, spontaneous anti-idiotypic
(anti-Id) antibodies (Ab2) can be detected in patient sera with high titers of anti-gp43. Since it has been
postulated that anti-Id antibodies may have a modulating function, we decided to purify and characterize
anti-Id antibodies in this system. The possible correlation of Ab2 titers with different clinical forms of disease
was also verified. Results showed that purified human anti-Id antibodies (human Ab2) recognized specifically
the idiotype of some murine monoclonal anti-gp43 (17c and 3e) but not others (40.d7, 27a, and 8a). Sponta-
neous anti-Id antibodies were found in all clinical forms of disease. The majority of patients (88%, n 5 8) with
the acute form of PCM had high titers of Ab2. However, among patients with the multifocal chronic form of
the disease, only 29% (n 5 14) had high titers of Ab2; 70% (n 5 10) of patients with the unifocal chronic form
had low titers of Ab2. A correlation between Ab2 titers and anti-gp43 titers was observed before and during
antimycotic treatment. Our results suggest that titers of anti-Id antibodies correlate with the severity of PCM
in humans.
Paracoccidioidomycosis (PCM) is a systemic mycosis re-
stricted to Latin America, with large areas of endemicity in
Brazil, Colombia, Venezuela, and Argentina (6, 31). The eti-
ologic agent of the disease is a thermal dimorphic fungus,
Paracoccidioides brasiliensis, which grows as a characteristic
multiple budding yeast in the host or at 37°C or as mycelium at
25°C (6). In spite of the lack of knowledge of the habitat of P.
brasiliensis, it is assumed that humans become infected via
inhalation of conidia present in the environment. Depending
on both host and pathogen factors, a wide spectrum of clinical
and pathological manifestations can be observed in these pa-
tients (25). In areas of endemicity, up to 60% of the population
acquires only asymptomatic infection, with positive paracoc-
cidioidin skin tests, while some individuals develop disease (15,
25). Two main clinical forms of the disease are recognized: the
acute or juvenile form (AF) and the chronic or adult form
(CF). The AF affects mainly children and young adults of both
sexes. This form is characterized by a rapid evolution and by
marked involvement of the mononuclear-phagocytic system
(spleen, liver, lymph nodes, and bone marrow). The CF occurs
mainly in adult males (approximately 80 to 90%) more than 35
years old. The disease progresses slowly and may take months
or even years to become fully established. The CF can be
restricted to only one organ (unifocal CF [UCF]) or dissemi-
nated to several organs or systems (multifocal CF [MCF]).
Most frequently, lesions occur in the lungs, oral and laryngeal
mucous membranes, skin, lymph nodes, and adrenal glands (6,
13, 31).
Diagnosis currently relies on direct microscopic examina-
tion, the ability to grow the fungus in the laboratory, and
serologic tests (15, 22, 27). Some of the recent serological
assays use the 43-kDa surface glycoprotein (gp43) (10, 11).
This glycoprotein is the major antigenic component of P. bra-
siliensis, since 100% of PCM patient sera display antibodies
against it. gp43 is a high-mannose concanavalin A-binding gly-
coprotein (30, 32, 33, 39, 43). Several biological functions have
been proposed for this molecule. Our group has characterized
gp43 as a laminin-binding protein implicated in fungal patho-
genesis in vivo (40). Others have shown that gp43 expresses
immunodominant epitopes eliciting T-cell-dependent delayed
hypersensitivity reactions, inducing a CD41 T-lymphocyte pro-
liferation response in humans and experimental animals (2,
37).
According to the idiotypic network hypothesis proposed by
Jerne (20), different antigenic determinants within variable
domains of immunoglobulins can be recognized and can elicit
an immune response in the same individual (5, 20). These
antigenic determinants are known collectively as idiotypes
(Ids). The potential immunoregulatory role of Id–anti-Id in-
teractions has been intensively investigated by several groups
(4, 21, 42).
Our group demonstrated that mice immunized with anti-
gp43 monoclonal antibodies (MAbs) (Ab1), shown to induce
the idiotypic cascade in the gp43 system, produced both anti-Id
antibodies (Ab2) and anti-anti-Id antibodies (Ab3). Moreover,
we found for the first time that PCM patient sera also dis-
played significant amounts of Ab2. Our results showed spon-
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taneous modulation of the idiotypic cascade in the gp43 system
of P. brasiliensis in both mice and humans (35).
Although we have demonstrated Ab2 in patients with PCM
(35), the possible correlation between the levels of Ab1 and
Ab2 in the different clinical forms of the disease has not been
investigated. Since anti-Id antibodies may have immunomodu-
lating functions, we decided to characterize the human anti-Id
antibodies in this system and verify their possible correlation
with different clinical forms of the disease. The results pre-
sented here demonstrate that all clinical forms of the disease
have spontaneous anti-Id antibodies and suggest a correlation
with the different clinical forms of the disease. Also, our data
suggest that anti-Id antibodies correlate with anti-gp43 titers.
MATERIALS AND METHODS
Human serum specimens. Individual serum specimens from 32 patients with
PCM (8 from patients with the AF, 10 from patients with the UCF, and 14 from
patients with the MCF) were selected based on clinical diagnosis of the disease
(6) and confirmed by positive direct examination of characteristic multiple bud-
ding yeast forms either in histopathologic sections or in biological fluids. All
patient sera were found positive for anti-gp43 antibodies by both the immuno-
diffusion test (9) and a capture enzyme immunoassay (EIA), which was shown to
be more sensitive and specific (10). These sera were collected before antimycotic
therapy. Five patients were given antimycotic therapy (three with itraconazole,
one with fluconazole, and one with a sulfamide derivative), and none was con-
sidered cured during the time span of this study. All serum specimens, from
healthy individuals or from PCM patients, were obtained from Instituto de
Medicina Tropical de Sa˜o Paulo or Hospital Sa˜o Paulo, Federal University of
Sa˜o Paulo.
MAbs. The anti-gp43 MAbs 17c, 40.d7, 27a, 3e, and 8a (all immunoglobulin
G2b [IgG2b], k light chain) (16, 29) and the anti-anti-carcinoembryonic antigen
MAb 6.C4 (IgG2b) (26) were used in EIAs. The anti-gp43 MAbs 17c and 8a were
also used for the purification of human anti-Id antibodies (Ab2) as described
below.
Purification of anti-gp43 antibodies from human PCM sera. Patient sera with
high titers of anti-gp43 antibodies were selected for purification by affinity chro-
matography. For this purpose, CNBr-activated Sepharose 4B (Pharmacia, Upp-
sala, Sweden) coupled to gp43 according to the manufacturer’s instructions was
used. Briefly, 5 ml of filtered patient sera adjusted to pH 8.2 was applied to the
column for 3 h. After a wash with 50 mM Tris base–0.15 M NaCl buffer (pH 8.2),
antibodies were eluted with 50 mM glycine–0.15 M NaCl buffer (pH 2.8). The
protein concentration was determined at 280 nm. All purified human anti-gp43
antibodies were tested for their ability to bind to gp43 in EIAs and immuno-
blotting tests as described below.
Purification of anti-Id antibodies (Ab2) from human PCM sera. Human
anti-Id antibodies were purified by affinity chromatography with CNBr-activated
Sepharose 4B coupled to both murine anti-gp43 MAbs 17c and 8a according to
the manufacturers’ instructions. For this purpose, patient sera with high titers of
anti-Id antibodies were selected.
Binding of purified human Ab1 to gp43 in the EIA. The EIA was performed
as described before (11). Briefly, polyvinyl microplates (Costar Corp., Cam-
bridge, Mass.) were coated with 2 mg of purified gp43 per ml in phosphate-
buffered saline (PBS, 50 ml/well) for 1 h at 37°C. Free sites were blocked with
PBS containing 1% bovine serum albumin (BSA) for 1 h at 37°C, followed by
treatment of the wells with 0 to 20 mg of purified human Ab1 per ml or 10 mg of
an IgG pool obtained from 20 healthy volunteers per ml (negative control) in a
final volume of 50 ml/well for 1 h at 37°C. After incubation, wells were washed
three times with PBS containing 0.5% gelatin (Difco Laboratories, Detroit,
Mich.) and 0.05% Tween 20 (Sigma Chemical Co., St Louis, Mo.) (PBS-Tw-G)
and then treated for 1 h at 37°C with 50 ml of goat anti-human IgG–horseradish
peroxidase conjugate (Bio-Rad Laboratories, Hercules, Calif.). Microplates were
then washed as described before, and reactions were developed with o-phenyl-
enediamine (Sigma) in 0.1 M acetate-phosphate buffer (pH 5.8) and interrupted
with 4 N H2SO4; results were read with a Titertek Multiscan EIA reader at 492
nm. Each datum point represents experiments done at least twice, always in
duplicate.
Binding of purified human Ab2 to murine anti-gp43 MAbs. Murine anti-gp43
MAbs 17c, 40.d7, 27a, 3e, and 8a were used in binding assays with purified human
Ab2. MAb 6.C4 (26) was used as an irrelevant MAb. Briefly, polyvinyl micro-
plates were coated with anti-gp43 MAbs and the irrelevant MAb (10 mg/ml, 100
ml/well) diluted in PBS for 1 h at 37°C. The remaining sites of wells were blocked
as described above, and 10 mg of purified human Ab2 per ml was added and
incubated for 1 h at 37°C. After three washes, wells were treated as described
before.
Inhibition by purified human Ab1 of binding of affinity-purified Ab2 to anti-
gp43 MAb 17c. Purified human Ab1 were used for the inhibition of binding of
purified human Ab2 to anti-gp43 MAb 17c in an EIA. Microplate wells were
coated with 20 mg of purified human Ab2 per ml (100 ml/well) and incubated for
1 h at 37°C. After blocking of free sites with PBS–1% BSA, 0 to 10 mg of murine
anti-gp43 MAb 17C per ml (50 ml/well) in the presence or absence of purified
human Ab1 (0.25, 2.5, or 10 mg/ml) was added. After incubation for 1 h at 37°C,
wells were exhaustively washed and treated for 1 h at 37°C with 100 ml of
anti-murine IgG coupled to peroxidase (Bio-Rad). Wells were further treated as
described above.
Detection of anti-gp43 antibodies in human PCM sera. PCM patient sera were
diluted 1:25,000 (vol/vol) in PBS and assayed by a capture EIA as described
before (11, 36). Briefly, polyvinyl microplates were coated with 20 mg of anti-
gp43 MAb 17c per ml in PBS (100 ml/well) for 1 h at 37°C. Free sites were
blocked with PBS–1% BSA, followed by treatment of the wells with 10 mg of
affinity-purified gp43 per ml (100 ml/well) for 1 h at 37°C. Wells were then
exhaustively washed with PBS-Tw-G and incubated overnight at 4°C with diluted
human PCM sera. After incubation, wells were treated as described above.
Detection of anti-Id antibodies (Ab2) in human PCM sera. All human PCM
sera or sera from healthy volunteers were serially diluted (volume/volume) in
PBS containing 0.1% BSA, and the presence of Ab2 was determined as described
before (35). Briefly, microplate wells were coated with 20 mg of murine anti-gp43
MAb 17c per ml (100 ml/well) for 1 h at 37°C and blocked as described above.
Wells were then incubated overnight at 4°C with diluted patient sera. Afterward,
the plates were treated with the conditions already mentioned.
SDS-PAGE and immunoblot analysis. Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) was performed on vertical slab gels of 10%
acrylamide, always under reducing conditions (23). Immunoblotting was per-
formed as described elsewhere (38).
Statistical analysis. Data were analyzed by the Student-Newman-Keuls mul-
tiple-comparisons test or by a one-way analysis of variance.
RESULTS
Characterization of purified human anti-gp43 antibodies.
Affinity-purified human Ab1 were characterized for their abil-
ity to bind to gp43 in both EIAs and immunoblotting tests.
They were able to bind to gp43 in an EIA with a saturation
tendency. A pool of IgG obtained from 20 healthy volunteers
and purified in Sepharose-protein A was used as a negative
control (Fig. 1). With immunoblotting, it was demonstrated
that purified human Ab1 recognized gp43 in both its integral
and its deglycosylated forms, thus showing that binding occurs
through peptidic epitopes of the molecule (data not shown).
Characterization of purified anti-Id antibodies (Ab2). In
order to characterize anti-Id antibodies, inhibition of the bind-
ing of affinity-purified human Ab2 to murine anti-gp43 MAb
17c (Ab1) by purified human anti-gp43 antibodies (Ab1) was
investigated. The binding of anti-gp43 MAb 17c to purified
human Ab2 showed a typical saturation curve that was inhib-
ited by purified human Ab1 in a dose-dependent pattern.
Moreover, at a purified human Ab1 concentration of 10 mg/ml,
FIG. 1. Binding of purified human anti-gp43 antibodies to gp43 in an EIA.
gp43 was recognized by purified human anti-gp43 antibodies at concentrations
ranging from 0 to 20 mg/ml. A pool of purified IgG from healthy individuals was
used as a negative control. Error bars show standard deviations. O.D., optical
density.
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binding inhibition was nearly 100% (Fig. 2). Purified human
Ab2 reacted with the idiotypes of MAbs 17c and 3e. However,
idiotypes of MAbs 40.d7 and 27a were not recognized. Al-
though human Ab2 were purified by affinity chromatography in
CNBr-activated Sepharose 4B coupled to MAbs 17c and 8a,
they did not recognize the MAb 8a idiotype. Finally, as ex-
pected, there was no significant binding to the irrelevant MAb
6.C4 (Fig. 3).
Detection of anti-gp43 antibodies (Ab1) and anti-Id anti-
bodies (Ab2) in PCM sera from humans with different clinical
forms of PCM. Figure 4a shows the anti-gp43 titers in sera of
patients with different clinical forms of PCM (all diluted
1:25,000). Confirming previous results (9), patients with the
AF of PCM had higher titers of anti-gp43 antibodies than
patients with the MCF and UCF (P, ,0.001). When the MCF
and the UCF were compared, the first showed higher anti-gp43
titers (P, ,0.01).
In order to verify whether the anti-Id pattern was similar to
the anti-gp43 pattern in the different clinical forms of PCM,
patient sera diluted 1:500 were used in EIAs as described in
Materials and Methods (Fig. 4b). Similar to the results found
for anti-gp43 antibodies, the anti-Id levels were higher in the
AF than in the CF of PCM (P, ,0.001). However, with this
serum dilution, no statistical difference was detected between
the MCF and the UCF (P, .0.05). All sera were previously
tested and did not react against BSA in the solid phase.
To corroborate these results, determination of titers of an-
ti-Id antibodies (Ab2) was carried out (Table 1). The majority
of AF patients (88%) had high titers ($1:8,000) of Ab2, while
only 29% of MCF patients and 0% of UCF patients did. Sev-
enty percent of patients with the UCF of PCM displayed low
titers (#1:2,000) of Ab2. Taken together, these results strongly
suggest a correlation between spontaneous anti-Id antibodies
and the severity of disease.
Correlation between Ab1 and Ab2 in patients with different
clinical forms of PCM. The correlation between anti-gp43 an-
tibodies (Ab1) and spontaneous anti-Id antibodies (Ab2) in
human PCM sera (before antimycotic treatment) was also in-
vestigated (Fig. 5). Figure 5a shows the results obtained for all
patient sera regardless of the clinical form of the disease. The
correlation coefficient for Ab1 and Ab2 (r, 0.7301) was consid-
ered extremely significant (P, ,0.0001). However, analysis of
FIG. 2. Inhibition of the binding of purified human anti-Id antibodies (Ab2)
to anti-gp43 MAb 17c by purified human anti-gp43 antibodies. Binding of 0.25 to
10 mg of anti-gp43 MAb 17c per ml to purified human anti-Id antibody (Ab2)-
coated plates was measured in the absence or presence of purified human
anti-gp43 antibodies. Data were obtained from a representative patient. Assays
were done in duplicate. Error bars show standard deviations. O.D., optical
density.
FIG. 3. Binding of purified human anti-Id antibodies (Ab2) to anti-gp43
MAbs. Plates coated with anti-gp43 MAbs 17c, 40.d7, 27a, 3e, and 8a were
assayed for recognition by purified human anti-Id antibodies (Ab2). Positive
reactions were only seen for MAbs 17c and 3e. MAb 6.C4 was used as a control.
This plot is representative of three independent experiments. Error bars show
standard deviations. O.D., optical density.
FIG. 4. Detection of anti-gp43 antibodies by a capture EIA (a) and anti-Id
antibodies (b) in sera of patients with different clinical forms of PCM. Sera of
healthy individuals were used as negative controls. Both assays were performed
with MAb 17c bound to the solid phase. Each datum point represents the result
for each patient. O.D., optical density. Means for both Ab1 and Ab2 are indi-
cated (horizontal lines).
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the clinical forms of PCM disclosed some particularities in that
correlation. As observed in Fig. 5b, there was a correlation
between Ab1 and Ab2 in the AF (r, 0.5761, P, 0.0195) as well
as in the MCF of the disease (r, 0.6434, P, 0.0002). Strikingly,
in the UCF, no significant correlation was observed even when
lower dilutions (1:10,000) were used for the Ab1 assay (data
not shown).
Follow-up of anti-gp43 and anti-Id antibodies in patients
given antimycotic therapy. Some PCM patients were serolog-
ically monitored along the course of treatment. Figure 6 shows
the anti-gp43 and anti-Id titers in five patients with the AF of
the disease after 0, 6, and 12 months of antimycotic therapy.
Results showed that both anti-gp43 and anti-Id levels decayed
in parallel along the treatment. Even after 12 months of ade-
quate treatment, there were significant amounts of both anti-
gp43 and anti-Id antibodies. Similar results were observed in
Fig. 7, which presents data obtained from a representative
patient during 42 months of antimycotic therapy.
DISCUSSION
In 1974, Jerne (20) postulated a hypothesis in which the
idiotypic network could have influence in immunoregulation.
According to Jerne’s hypothesis, lymphocyte antigen receptors
(i.e., immunoglobulin on B cells and T-cell receptor on T cells)
express antigenic determinants which are potentially immuno-
genic; i.e., humoral and cellular immune responses in an indi-
FIG. 5. Correlation between anti-gp43 antibodies (Ab1) and anti-Id antibod-
ies (Ab2) in sera of patients with PCM before antimycotic therapy. Analysis of
the correlation was performed for all patient sera regardless of clinical forms
(n 5 32) (a) or with consideration of clinical forms: AF (n 5 8) and MCF (n 5
14). O.D., optical density.
FIG. 6. Follow-up of anti-gp43 antibody (Ab1) and anti-Id antibody (Ab2)
titers in patients given antimycotic therapy. Sera of patients with the AF of PCM
were assayed for the presence of anti-gp43 and anti-Id antibodies at 0, 6, and 12
months after antimycotic treatment. Datum points represent optical density
(O.D.) values minus the average O.D. (0.174) obtained for normal sera diluted
1:1,000 for Ab2 tests. Lines indicate mean values for both Ab1 and Ab2.
FIG. 7. Follow-up of anti-gp43 antibody (Ab1) and anti-Id antibody (Ab2)
titers in a representative patient given antimycotic therapy. Sera of patients with
the AF of PCM were assayed for the presence of anti-gp43 and anti-Id antibodies
at 0, 4, 6, 12, 18, 24, and 42 months after antimycotic treatment. Datum points
represent optical density (O.D.) values minus the average O.D. (0.149) obtained
for normal sera diluted 1:1,000 for Ab2 tests. Error bars indicate standard
deviations.
TABLE 1. Presence of anti-Id antibodies in sera from untreated
patients with different clinical forms of PCM
Clinical form Classificationof Ab2 titersa
No. (%) of
Ab2-positive patients
AF (n 5 8) High 7 (88)
Medium 1 (12)
Low 0 (0)
MCF (n 5 14) High 4 (29)
Medium 2 (14)
Low 8 (57)
UCF (n 5 10) High 0 (0)
Medium 3 (30)
Low 7 (70)
a High, $1:8,000; medium, 1:4,000; low, #1:2,000.
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vidual can be induced against antigen receptors expressed by
the lymphocytes of that same individual. These antigenic de-
terminants are known collectively as Ids. Jerne’s network the-
ory predicts that anti-Id antibodies (Ab2), bearing the internal
image of the corresponding antigen, are able to induce immu-
nity to the original antigen in hosts not previously exposed to
it (19, 20, 28). It has been suggested that the immune response
can be modulated at the level of recognition of idiotype deter-
minants via the idiotype–anti-idiotype network (4, 21). While
there is substantial evidence indicating that anti-Id antibodies
are normal components of the immune response, their signif-
icance in its regulation remains unclear (29, 34). Although it is
generally assumed that spontaneous anti-Id antibodies, which
arise in an intact network, will decrease immune responses
associated with a particular Id, anti-Id antibodies may also
have the capacity to increase immune responses (12, 14).
Recent studies showed that the course of PCM is under
genetic control (7). It was shown that an autosomal dominant
gene controls resistance or susceptibility to the disease. It is
assumed that in resistant mice, which carry the Pbr (P. brasil-
iensis resistance) gene, the immune response is directed to Th1
activation, with consequent resolution of the disease. Suscep-
tible mice, which carry the P. brasiliensis susceptibility (Pbs)
gene, would mount predominantly a Th2 type of immune re-
sponse, leading to progressive disease (7, 8). It has been dem-
onstrated by our group and by others (24) that PCM patients
show high levels of antibodies directed against gp43 (Ab1), the
major antigenic component of the fungus. We also recently
demonstrated the existence of significant titers of anti-Id an-
tibodies (Ab2) in those patients (35).
Since spontaneous anti-Id antibodies can play a significant
role in the immune response against several pathogens and
also because anti-Id antibodies can be responsible for high
titers of antibodies in several infections (1, 41), we decided to
further characterize human Ab1 and Ab2 in PCM. For this
purpose, sera of PCM patients with the AF, MCF, and UCF of
the disease were evaluated in this study.
In order to better characterize both human anti-gp43 anti-
bodies (Ab1) and anti-anti-gp43 antibodies (Ab2), sera from
untreated PCM patients displaying high titers of anti-gp43
antibodies were affinity purified using Sepharose coupled with
purified gp43 or with murine anti-gp43 MAbs, respectively. As
expected, affinity-purified human anti-gp43 antibodies recog-
nized specifically the antigen (gp43) in an EIA. It was observed
that when increasing amounts of affinity-purified human anti-
gp43 antibodies were assayed, a “plateau” was reached after
the addition of .5 mg of anti-gp43 antibodies per ml, strongly
suggesting saturation (Fig. 1). Moreover, the affinity-purified
human anti-gp43 antibodies were able to specifically recognize
deglycosylated gp43, suggesting that the majority of them are
directed against peptidic regions of the antigen, as observed in
mice (35). Considering our previous observation with mice
showing that Ab2 could also induce Ab3 production (35), we
cannot rule out the possibility that affinity-purified human
polyclonal antibodies recognizing specifically gp43 could be a
mixture of both Ab1 and Ab3.
Spontaneously produced anti-Id antibodies (Ab2) were also
affinity purified and characterized. As expected, results showed
that the purified human Ab2 were able to specifically recognize
the idiotype of murine anti-gp43 MAb 17c. When .1.0 mg/ml
was added, a typical saturation plot was obtained. This binding
was inhibited by purified human anti-gp43 antibodies in a dose-
dependent pattern. Furthermore, at a concentration of 10 mg
of purified human Ab1 per ml, binding inhibition was close to
100% (Fig. 2). These findings suggest that purified human
anti-Id antibodies are directed against antigenic determinants
on the binding site (idiotopes) of human anti-gp43 antibodies
and also that the majority of them probably bear the internal
image of the antigen (gp43). Anti-Id antibodies with these
properties are classified as Ab2b. It has been assumed that
Ab2b are able to elicit immune responses against the original
antigen and therefore potentially have an immunoregulatory
function (3, 5, 28).
The specificity of purified human anti-Id antibodies was also
confirmed through their binding to several murine anti-gp43
MAbs (Fig. 3). Purified human Ab2 recognized MAbs 17c and
3e but not MAbs 40.d7 and 27a although, as demonstrated
before, these anti-gp43 antibodies compete with MAb 17c in
gp43 peptide recognition (17). These results demonstrated that
different antibodies can recognize the same epitope, without
sharing the same idiotype, confirming our previous results ob-
tained with mice (35). On the other hand, purified human
anti-Id antibodies were not able to recognize MAb 8a, even
though they were affinity purified in a column coupled to both
MAbs 8a and 17c. Several possibilities can explain this phe-
nomenon, such as the amount and affinity of Ab2 for MAb 8a
present in the human sera, the amount of MAb 8a bound to
the column, and the lack of a similarly immunogenic MAb 8a
idiotype in humans.
The fact that purified human anti-Id antibodies recognize
some but not all idiotypes of murine anti-gp43 MAbs strongly
suggests that at least some idiotypes are conserved in humans.
Other studies have demonstrated that certain idiotypes appear
on a large proportion of antibody molecules in several individ-
uals of the same or of different species; such idiotypes are
known as public, recurrent, dominant, or cross-reactive (CR)
idiotypes (CRI) (21). The importance of CRI in the pathogen-
esis of disease or in immunoregulation has been demonstrated
in several systems (1, 18, 41). Many but not all antibodies
bearing CRI in these disease models are encoded by germ line
gene sequences (1, 18). The results reported here imply the
existence in gp43 of dominant epitopes that induce conserved,
possibly germ line gene-encoded, humoral responses in hu-
mans and mice, as has been postulated for the antibacterial
T151 Id-bearing antibody responses of mice and humans (18).
After characterization of human anti-Id antibodies (Ab2),
the possible correlation of Ab1 and Ab2 titers in patient sera
with different clinical forms of PCM was investigated. As dem-
onstrated before by others (10), our results confirmed that
anti-gp43 titers correlate with clinical forms of the disease (Fig.
4a). Since anti-gp43 antibodies (Ab1) can elicit an anti-Id an-
tibody response (Ab2) we investigated whether the anti-Id
pattern parallels the anti-gp43 pattern. It was observed that
anti-Id antibody levels also correlate with the clinical forms of
the disease (Fig. 4b). In order to further characterize this
correlation, Ab2 titers were determined. The results showed
that 88% of patients with the AF of PCM had high titers
($1:8,000) of spontaneous anti-Id antibodies (Ab2), while only
29% of patients with the MCF and 0% of patients with the
UCF did. In contrast, 70% of patients with the UCF of PCM
had low titers (#1:2,000) of Ab2 (Table 1). Since there is a
correlation between anti-Id titers and the clinical forms of the
disease, analysis of the titers of spontaneous anti-Id antibodies
(Ab2) might be of importance for the prognosis of the disease.
Considering that the anti-gp43 pattern and the anti-Id pat-
tern in different clinical forms of PCM are similar (Fig. 4), the
possibility of a correlation between them was addressed. When
all patient sera were considered regardless of the clinical form,
the correlation was extremely significant (Fig. 5a). However,
some differences were observed when each of the clinical forms
of PCM was individually analyzed. In the AF and MCF, there
was a significant correlation between anti-gp43 and anti-Id
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titers (Fig. 5b). However, no significant correlation was ob-
served for the UCF (data not shown).
Some patients may have persistent significant titers of anti-
gp43 antibodies even after prolonged treatment and with clin-
ical and mycological cure (Z. P. Camargo and J. R. Alves,
personal communication). The stimulation of the idiotypic cas-
cade could be responsible for the persistence of anti-gp43
antibodies in these patients. To address this question, patients
with the AF of PCM were serologically monitored during treat-
ment. Both anti-gp43 and anti-Id titers decayed in parallel with
therapy. Nevertheless, even after several months of adequate
treatment, there were still significant levels of Ab2 (Fig. 6 and
7). These results suggest that Ab2 can elicit anti-gp43 antibody
production after antigen elimination. It seems that spontane-
ous anti-Id titers also correlate with anti-gp43 titers during
treatment.
Studies of patients with schistosome infection showed that
those with acute infection or hepatosplenic disease had high
levels of antibodies to soluble egg antigen (SEA) and low titers
of anti-Id antibodies, whereas patients with the asymptomatic
form of disease had low titers of anti-SEA antibodies and high
titers of anti-Id antibodies (41). The authors suggested that the
failure to modulate the expression of anti-SEA antibodies and
produce high levels of immunomodulatory anti-Id antibodies
during chronic infection correlates with severe schistosome-
induced disease (41).
Because more severe forms of PCM had higher anti-Id titers
and because there was a correlation between anti-gp43 and
anti-Id antibodies, one can assume that in PCM anti-Id anti-
bodies are not sufficient to modulate the immune response.
However, it must be considered that the anti-Id antibodies
studied here recognized only idiotypes similar to the idiotypes
of murine anti-gp43 MAb 17c. Therefore, we cannot rule out
the possibility of the existence in humans of different anti-Id
antibodies directed against other anti-gp43 antibodies (Ab1)
with a role in the pathogenesis of the infection or in its immu-
noregulation. Specific studies about the importance of the anti-
idiotypic network in fungal pathogenesis are now being carried
out in our laboratory.
Spontaneous idiotypic modulation is not a common feature
in all systems, as our group has already shown (35). For PCM,
we have demonstrated for the first time that the idiotypic
network is unleashed after infection by the fungus in both mice
and humans (35). In the present work, it was shown that there
are spontaneous anti-Id antibodies (Ab2) in humans with dif-
ferent clinical forms of the disease and that there is a correla-
tion between some forms and the severity of disease which
could be useful for clinical evaluation.
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